V
Violaine Planté-Bordeneuve
Researcher at University of Paris-Sud
Publications - 85
Citations - 7559
Violaine Planté-Bordeneuve is an academic researcher from University of Paris-Sud. The author has contributed to research in topics: Transthyretin & Amyloidosis. The author has an hindex of 33, co-authored 64 publications receiving 5774 citations. Previous affiliations of Violaine Planté-Bordeneuve include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David Adams,Alejandra González-Duarte,William O'Riordan,Chih-Chao Yang,Mitsuharu Ueda,Arnt V. Kristen,Ivailo Tournev,Hartmut Schmidt,Teresa Coelho,John L. Berk,Kon Ping Lin,Giuseppe Vita,Shahram Attarian,Violaine Planté-Bordeneuve,Michelle M. Mezei,Josep M. Campistol,Juan Buades,Thomas H. Brannagan,Byoung Joon Kim,Jeeyoung Oh,Yesim Parman,Yoshiki Sekijima,Philip N. Hawkins,Scott D. Solomon,Michael Polydefkis,Peter J. Dyck,Pritesh Gandhi,Sunita Goyal,Jihong Chen,Andrew Strahs,Saraswathy V. Nochur,Marianne T. Sweetser,Pushkal Garg,Pushkal Garg,Akshay Vaishnaw,Akshay Vaishnaw,Jared Gollob,Ole B. Suhr +37 more
TL;DR: Patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis with polyneuropathy and showed an effect on gait speed and modified BMI.
Journal ArticleDOI
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Merrill D. Benson,Márcia Waddington-Cruz,John L. Berk,Michael Polydefkis,Peter J. Dyck,Annabel K. Wang,Violaine Planté-Bordeneuve,Fabio Barroso,Giampaolo Merlini,Laura Obici,Morton A. Scheinberg,Thomas H. Brannagan,William J. Litchy,Carol J. Whelan,Brian M. Drachman,David C. Adams,Stephen B. Heitner,Isabel Conceição,Hartmut H. Schmidt,Giuseppe Vita,Josep M. Campistol,Josep Gamez,Peter D. Gorevic,Edward Gane,Amil M. Shah,Scott D. Solomon,Brett P. Monia,Steven G. Hughes,Jesse Kwoh,Bradley W. McEvoy,Shiangtung W. Jung,Brenda F. Baker,Elizabeth J. Ackermann,Morie A. Gertz,Teresa Coelho +34 more
TL;DR: Inotersen improved the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis and improvements were independent of disease stage, mutation type, or the presence of cardiomyopathy.
Journal ArticleDOI
Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial
Teresa Coelho,Luis F. Maia,Ana Martins da Silva,Márcia Waddington Cruz,Violaine Planté-Bordeneuve,Pierre Lozeron,Ole B. Suhr,Josep M. Campistol,Isabel Conceição,Hartmut Schmidt,Pedro Trigo,Jeffery W. Kelly,Richard Labaudinière,Jason Chan,Jeff Packman,Amy Wilson,Donna R. Grogan +16 more
TL;DR: This study provides Class II evidence that 20 mg tafamidis QD was associated with no difference in clinical progression in patients with TTR-FAP, as measured by the NIS-LL and the Norfolk QOL-DN score, supporting the hypothesis that preventing TTR dissociation can delay peripheral neurologic impairment.
Journal ArticleDOI
Guideline of transthyretin-related hereditary amyloidosis for clinicians
Yukio Ando,Teresa Coelho,John L. Berk,Márcia Waddington Cruz,Bo Göran Ericzon,Shu-ichi Ikeda,W. David Lewis,Laura Obici,Violaine Planté-Bordeneuve,Claudio Rapezzi,Gérard Said,Fabrizio Salvi +11 more
TL;DR: Providing guidance on making a definitive diagnosis, methods for disease staging and evaluation of disease progression, and discuss symptom mitigation and treatment strategies, including liver transplant and several pharmacotherapies that have shown promise in clinical trials are provided.
Journal ArticleDOI
Familial amyloid polyneuropathy
TL;DR: Oral administration of tafamidis meglumine, which prevents misfolding and deposition of mutated TTR, is under evaluation in patients with TTR FAP, and genetic counselling is recommended for the prevention of all types of FAP.